Document Actions
July 2009 Institutional newsletter
Welcome to the July 2009 Institutional Newsletter.
An update from the BMJ Group.
If you require any assistance in promoting BMJ Group products to your users, please do not hesitate to contact Genie Powers who can supply a number of resources.
What's new this month?
Breaking News - BMJ is voted as one of the top 10 most influential journals
Evidence in Practice newsletter
BMJ Group's free authoritative guide to swine flu
BMJ and BMJ Journals ISI Impact Factors announced
Breaking News - BMJ selected in the top 10 most influential journals of the last 100 years in medicine and biology
The Specialists Library Association, SLA, a professional organisation of subject specialist librarians, information managers, and publishing industry representatives, selected the 100 most influential biological and medical journals for its 100th anniversary meeting. BMJ, along with NEJM, JAMA and Lancet, were among those selected and BMJ made it into the top 10 list.
Best Practice
Best Practice is continually updated to ensure users are accessing the most up-to-date information when they need it.
This month we have added a further 15 topics to the site which include
All updates are now available online
Best Practice is designed to provide clinicians with a second opinion. There are a number of ways to access Best Practice ensuring clinicans have all the information at their fingertips.
Roaming access
Users can now access Best Practice when off-site at no extra cost. To add this to your subscription, contact BMJ Group customer services and request roaming access be enabled. More information is available in the Best Practice 'Institutional Administrator userguide'
Best Practice on your mobile
A specially optimised version of Best Practice has been developed so that users can access the site on their mobile. For details on how to add this to your institutional subscription, please view the userguide. For more information on a free trial, purchasing Best Practice or if you would like promotional materials please contact consortiasales@bmjgroup.com
BMJ Case Reports
Why sign up?
Here are 6 great reasons why your institution should ask for a free trial to BMJ Case Reports
- Cost effective way of raising the profile of your institution
- Highlight the work of your clinicians
- Eases the publishing pathway for junior doctors
- Share clinician experiences
- Clinicians can submit as many case reports as they like
- Growing repository of case reports
Help to grow this pioneering community. To arrange a free trial for your institution contact consortiasales@bmjgroup.com
or tel: +44 (0) 20 7383 6693
Publishing, sharing and learning through experience
DTB (Drug and Therapeutics Bulletin)
The new look homepage, enables users to easily:
- find the latest issue
- access online first articles
- access the full back archive quickly
Plus a 50% increase in content and a new editorial and podcasts
Send your users to the site today to take advantage of the new features.
If you would like more information regarding a subscription to DTB, please contact consortiasales@bmjgroup.com
or tel: +44 (0) 20 7383 6693
Evidence in Practice newsletter
This month, we are pleased to announce the expansion in scope of our Evidence in Practice newsletter, which now represents all the activities of the BMJ Evidence Centre. Issue 4 has just published, and includes an editorial by Dr Klara Brunnhuber, explaining how and why we work to build evidence into practice, and an interview with Professor Paul Garner, an expert in infectious diseases. Check out the online edition now.
If you would like any printed copies to display in your institution, please contact Genie Powers.
Swine Flu
For continually updated information, including news, evidence summaries, podcasts, blogs, articles and discussions between doctors, please refer to 'BMJ Group's FREE authoritative guide to swine flu'
New impact factors announced
BMJ has increased its Impact Factor to 12.287 from 9.723 whilst our specialty titles such as Annals of Rheumatic Disease has increased its impact factor to 7.188 now making it the number 1 rheumatology journal, and Tobaccoo Control has increased its impact factor to 4.468 overtaking the leading US journal in this field.
